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The angiogenic factors vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) are respectively up- and
downregulated by hypoxia. We aimed to study circulating levels of the above factors in intrauterine growth restriction (IUGR) and
to correlate their levels with the customized centiles of the infants. The study included 25 IUGR and 25 appropriate for gestational
age (AGA) full-term, singleton infants and their mothers. Maternal (MS), fetal (UC), and neonatal day 1 (N1) and 4 (N4) blood was
examined. MS and N1 PlGF, as well as UC VEGF levels correlated with the customized centiles of the infants (r = 0.39, P = .007,
r = 0.34, P = .01, and r =− 0.41, P = .004, resp). Furthermore, UC, N1, and N4 VEGF levels were higher in girls (r = 0.36,
P = .01, r = 0.33, P = .02, and r = 0.41, P = .005 resp). In conclusion, positive and negative correlations of examined factors with
the customized centiles of the infant could rely on placental function and intrauterine oxygen concentrations—both being usually
lower in IUGR cases—while higher VEGF levels in girls should possibly be attributed to the stimulating action of estrogens.
INTRODUCTION
Vascular endothelial growth factor (VEGF), a key an-
giogenic factor in physiological and pathological condi-
tions, exists in ﬁve isoforms of 121, 145, 165,189, and 206
amino acids [1]. VEGF exerts its eﬀects by binding with
high aﬃnity to two tyrosine kinase receptors, VEGFR-
1/Flt-1 [2] and VEGFR-2/KDR [3], present on endothe-
lial cells [4]. VEGF has been demonstrated to be a potent
stimulator of endothelial cell proliferation [5]a n dp r o -
duction of the plasminogen activators, required for prote-
olytic degradation of the extracellular matrix [6]. Both of
these actions are markers of angiogenic activity. Particu-
larly, branching angiogenesis mediated by VEGF is due to
its binding to both Flt-1 and KDR receptors. The expres-
sion of VEGF and KDR is more pronounced during early
gestation, particularly the ﬁrst two trimesters, and decline
with progression of pregnancy [7].
Placenta growth factor (PlGF) belongs to the same
family and shares with VEGF 53% homology [8]. It has
been shown to be a very weak stimulator of endothelial
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cell chemotaxis and proliferation at physiological concen-
trations [9, 10]. On the other hand, PlGF potentiates the
actionoflowdosesofVEGFonmicrovascularendothelial
cells [11]. PlGF binds Flt-1 but not KDR [11] and results
innonbranchingangiogenesis[12,13].PlGFandFlt-1ex-
pression increases in the last trimester, towards term [14].
Oxygen is thought to be a major regulator of the bal-
ancebetweenVEGFandPlGFfunction[15].PlGFexpres-
sion is stimulated under elevated PO2 and downregulated
by a low PO2 [15, 16], whereas VEGF and its receptors are
upregulated by a low PO2 [17].
Intrauterine growth restriction (IUGR) is commonly
associated with an altered placental angiogenesis, due to
impaired placental oxygenation [18]. In addition, IUGR
is a signiﬁcant cause of infant mortality and morbidity
[19]. The majority of IUGR cases present an asymmet-
ric pattern of growth, usually associated with abnormali-
ties in placental structure and function. The latter are re-
sponsible for deprivation of the developing fetus of suﬃ-
cientoxygenandnutrients,requiredforhisorheroptimal
growth [20].
Inthisstudy,wehypothesizedthatcirculatinglevelsof
VEGF and PlGFin IUGR fetusesand neonates should dif-
fer from respective levels found in appropriate for gesta-
tional age (AGA) fetuses and neonates, as the former suf-
fer from in utero hypoxia and present restricted growth
and development. Therefore, we aimed to determine and294 Ariadne Malamitsi-Puchner et al 2005:5 (2005)
Table 1.Demographicdataofparticipatinginfants(intrauterinegrowth-restricted(IUGR),orappropriateforgestationalage(AGA))
and of their mothers.
IUGR n = 25 AGA n = 25
Maternal age (years) 30.9 ±5.5∗ 28.9 ±3.7∗
Gestational age (weeks) 38.2 ±1.7∗ 38.9 ±1.8∗
Birth weight (g) 2273 ±258.7∗ 3518 ±186.6∗
Gender (male/female) 12/13 14/11
Mode of delivery (VD/ECS)∗∗ 15/10 12/13
∗ values are mean ± SD.
∗∗ V D :v a g i n a ld e l i v e r y /E C S :e l e c t i v ec e s a r e a ns e c t i o n .
correlate circulating levels of VEGF and PlGF in IUGR
and AGA neonates at time points characteristic for intra-
and extrauterine life.
MATERIALS AND METHODS
The study was approved by the Ethics Committee of
our teaching hospital and informed consent was acquired
from participating mothers.
The study was comprised of 25 IUGR and 25 AGA
full-term, singleton infants, born from October 2003 to
April 2004, as well as their mothers, all of Greek ethnicity.
As IUGR were characterized infants below the 10th cus-
tomized centile for birth weight. For the calculation of the
customizedcentiles,theprinciplesofthegestation-related
optimal weight (GROW) program [21, 22]w e r eu s e d .
This is a computer-generated antenatal chart that can be
customized for each pregnancy, taking into consideration
signiﬁcant determinants of birth weight: gestational age,
gender, maternal weight at the beginning of pregnancy,
maternal height, ethnic group, and parity. These param-
eters are entered into the program to adjust the normal
birth weight centile limits [21].
The cause of intrauterine growth restriction was iden-
tiﬁed in each one of our 25 IUGR neonates. The personal,
family, and perinatal histories of each parturient were
considered and maternal ultrasounds and Doppler stud-
iesoftheumbilicalandmiddlecerebralarterythroughout
pregnancy were evaluated. Blood ﬂow studies were in all
included cases within normal ranges.
All included in this study IUGR cases were of the
asymmetrical pattern. IUGR resulted in 19 cases from
hypertension of pregnancy or preeclampsia and in three
cases from type I diabetes mellitus. In three further
IUGR cases, mothers presented no evident pathological
symptoms, but their placentas were very small (< 200g)
and infarcted, despite exclusion of intrauterine infection.
However, in all IUGR cases placentas weighed less than
400g and were infarcted. Among the 25 mothers, who
gave birth to IUGR infants, four reported smoking 5–10
cigarettes per day. In the group of AGA infants, moth-
ers were healthy and three smoked up to 5 cigarettes per
day. All placentas were weighed and carefully examined
for any sign of malformation. In all IUGR cases placentas
were small (less than 400g) and infarcted. Neonates were
examined for possible pathological causes leading to re-
striction, as intrauterine infection or genetic syndromes.
Latter cases were excluded from the study. One and ﬁve
minute Apgar scores were in all IUGR and AGA cases ≥ 7
and ≥ 8r e s p e c t i v e l y .
Demographic data of participating infants, as well as
of their mothers are given in Table 1.
Blood was drawn by venipuncture from the mothers
(MS) during the ﬁrst stage of labor or before anesthe-
sia in cases of elective cesarean section, from the doubly
clampedumbilicalcord(UC-mixedarteriovenousblood),
reﬂectingfetalstate,andfromtheneonatesondays1(N1)
and 4 (N4), characteristic for transition and stabilization
to extrauterine life, respectively.
Blood was collected in pyrogen-free tubes and was
immediately centrifuged after clotting. The supernatant
serum was kept frozen at −80◦ until assay. The determi-
nation of VEGF and PlGF was performed by enzyme im-
munoassay (Quantikine human VEGF, Catalog number
DVEOO and Quantikine human PlGF, Catalog number
DPGOO, R&D Systems, Minneapolis, Minn). The mini-
mum detectable concentration, intra-and interassay coef-
ﬁcients of variation were for VEGF < 5pg/mL,6.7%and
8.8%andforPlGF< 7pg/mL,7%and11.8%respectively.
For each blood sample drawn, a whole blood count
(including platelet count) was also performed.
DATA ANALYSIS
As not all data presented normal distribution (Kol-
mogorov-Smirnov test), nonparametric Spearman rank
correlation test was applied in the analysis. P values <. 05
were considered as signiﬁcant.
RESULTS
Figures 1 and 2 show the median and ranges of deter-
mined parameters in the two groups (IUGR and AGA).
Platelet counts were in all cases within normal ranges
(mean ± SEM ×103/mL; AGA MS: 265 ± 2.3, IUGR MS:
273±3.0, AGA UC: 312±3.1, IUGR UC: 323±2.8, AGA
N1: 290 ± 4.8, IUGR N1: 302 ± 3.5, AGA N4: 275 ± 2.9,
IUGR N4: 273 ±2.3).
Statistical signiﬁcant diﬀerence was noted in MS
PlGF, being lower in IUGR as compared to AGA cases2005:5 (2005) VEGF and PlGF in IUGR 295
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Figure 1. Median circulating levels of vascular endothelial
growth factor (VEGF (pg/mL)) in the four investigated groups:
maternal serum (MS), umbilical cord serum (UC), neonatal day
1 serum (N1), and neonatal day 4 serum (N4) for intrauterine
growth-restricted (IUGR) and appropriate for gestational age
(AGA) infants.
(P = .014). MS PlGF values were positively correlated
with the centile of the infant (r = 0.39, P = .007), and
his or her birth weight (r = 0.40, P = .006). Further-
more,MSPlGFvalueswerenegativelycorrelatedwithma-
ternal weight at the beginning of pregnancy (r =− 0.30,
P = .03). In addition, UC PlGF values were correlated
with neonate’s gender, being higher in boys (r =− 0.33,
P = .01), and N1 PlGF values were positively correlated
with the centile (r = 0.34, P = .01).
On the other hand, MS VEGF values were negatively
correlated with maternal weight (r =− 0.36, P = .01)
and UC VEGF values were negatively correlated with the
centile of the infant (r =− 0.41, P = .004), and also
with the birth weight (r =− 0.30, P = .03). Further-
more, UC VEGF values were positively correlated with
maternal age (r = 0.32, P = .02), and they were higher
in girls (r = 0.36, P = .01). As for N1 VEGF values,
they were higher in girls (r = 0.33, P = .02), while N4
VEGF values were positively correlated with maternal age
(r = 0.28, P = .04) and were also higher in girls (r = 0.41,
P = .005).
DISCUSSION
To our knowledge, this is the ﬁrst study to determine
VEGF and PlGF circulating levels in IUGR and AGA in-
fants, as well as their mothers.
According to our results, mothers, giving birth to
IUGR infants, demonstrate lower PlGF circulating levels
than mothers of AGA infants. This ﬁnding is in agree-
ment with previous studies, reporting that preeclampsia
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Figure 2. Median circulating levels of placenta growth fac-
tor (PlGF (pg/ml)) in the four investigated groups: maternal
serum (MS), umbilical cord serum (UC), neonatal day 1 serum
(N1), and neonatal day 4 serum (N4) for intrauterine growth-
restricted (IUGR) and appropriate for gestational age (AGA) in-
fants.
and small-for-gestational-age pregnancies are associated
with reduced serum levels of PlGF [23, 24], due to patho-
logic and smaller placentas [25]. The results of this study
extend the existing knowledge by documenting a positive
correlation of MS PlGF levels with the centile of the in-
fant, as well as with his or her birth weight.
Severalstudiesadvocatethatestrogensincreasetheex-
pression of VEGF in the uterus [26, 27]. Other studies
have shown that preeclampsia is characterized by reduced
levels of estrogens [28] and thus, in IUGR cases due to
preeclampsia, estrogens as well as MS VEGF should be
decreased. The negative correlation of MS VEGF and also
MS PlGF levels with maternal weight at the beginning of
pregnancy might be interpreted on the basis of the higher
risk for preeclampsia in obese pregnant women [29].
Studies on circulating VEGF levels in pregnant
womenprovidecontradictoryresultsconcerningsuppres-
sion of VEGF [30, 31, 32], presumably by the soluble
VEGFR-1 protein, produced and secreted by trophoblasts
[33]. In this study, we could demonstrate the presence of
circulating VEGF in mothers of both IUGR and AGA in-
fants. However, the origin of the determined VEGF is not
clear and could also derive from other sources, such as the
ovary [34], and the breast [35]. Nevertheless, MS VEGF
levels were not found to correlate with the infant’s centile.
The positive correlation of N1 PlGF levels with the
centile and respectively the negative correlation of UC
VEGF with the centile could be attributed to the chronic
inuteroactionofoxygen,sincehypoxia,usuallypresentin
IUGR cases, downregulates PlGF and upregulates VEGF
in contrast to normoxia [16, 17, 18]. In this study we did296 Ariadne Malamitsi-Puchner et al 2005:5 (2005)
not consider oxygen concentrations in the blood samples
drawn, since these would only represent the current, but
not the chronic oxygenation status of the fetal tissues.
The ﬁnding of signiﬁcantly higher UC PlGF levels
in boys cannot be explained based on existing litera-
ture, while the increased UC, N1, and N4 VEGF levels
in girls may rely on stimulated VEGF expression by es-
trogens [36]. In this respect, the fetal ovary might play a
role [37, 38]. However, a previous study of us [32] did
not ﬁnd a prevalence of VEGF in girls, as compared to
boys.
Our last ﬁnding that UC and N4 VEGF levels were
positively correlated with maternal age is to our knowl-
edge reported for the ﬁrst time. It could be explained tak-
ingintoconsiderationthatagedmothersareathigherrisk
for pregnancy complications, among them preeclampsia
a n dI U G R[ 39] and consequently restricted fetal oxygena-
tion,stimulatingVEGFsecretion.Nevertheless,theup-or
downregulation of VEGF production in IUGR cases is a
complicated mechanism, where several factors are impli-
cated.
Lastly, it should be stressed that in this study platelet
counts were in all cases within normal ranges and ele-
vatedVEGFlevelscannotbeattributedtoelevatedplatelet
counts [40].
In conclusion, according to this study, MS and N1
P l G F ,a sw e l la sU CV E G Fl e v e l sc o r r e l a t ew i t ht h ec e n t i l e
of the infant in positive and negative directions respec-
tively, possibly due to placental function and intrauter-
ine oxygen concentrations, both being usually lower in
IUGR cases. Furthermore, UC, N1, and N4 VEGF levels
are found higher in girls, possibly due to the stimulating
action of estrogens. Further studies are needed to verify
above results.
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